748Wire StoriesDraganfly Signs $9 Million Exclusive Manufacturing Agreement with Digital Dream Labs
Los Angeles, CA., Oct. 12, 2021 (GLOBE NEWSWIRE) — Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8) (“Draganfly” or the “Company”), an...
- 607Wire Stories
Gilat to Report Third Quarter 2021 Results on November 9th
PETAH TIKVA, Israel, Oct. 12, 2021 (GLOBE NEWSWIRE) — Gilat Satellite Networks Ltd. (NASDAQ, TASE: GILT), a worldwide leader in satellite networking...
- 808Wire Stories
Canva Launches Video Suite to Empower Everyone to Create, Edit and Record Stunning Videos
68% of U.S. knowledge workers say video is becoming increasingly important in the workplace SYDNEY–(BUSINESS WIRE)–Canva, the visual communications platform, today launched...
- 601Wire Stories
VIQ Solutions Announces Agreement to Acquire Assets of Court Recording and Transcription Services Company Auscript Australasia Pty Ltd
PHOENIX, Ariz.–(BUSINESS WIRE)–VIQ Solutions Inc. (“VIQ” or the “Company”) (TSX and Nasdaq: VQS), a global provider of secure, AI-driven, digital voice and...
- 813Wire Stories
Xperi Licenses Hybrid Bonding Technology to Yangtze Memory Technologies Co., Ltd. (YMTC)
Direct Bond Interconnect (DBI®) hybrid bonding portfolio licensed to YMTC for its 3D NAND memory products SAN JOSE, Calif.–(BUSINESS WIRE)–Xperi Holding Corporation™...
- 626Wire Stories
Seagen and Astellas Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV® (enfortumab vedotin-ejfv) With Pembrolizumab as First-Line Treatment for Advanced Urothelial Cancer
BOTHELL, Wash. & TOKYO–(BUSINESS WIRE)–Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that...
- 688Wire Stories
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 3b Study for ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
– Phase 3b dosing of ARCT-154 initiated; study designed to enroll approximately 20,000 participants – Initiation of Phase 3b study follows review...
- 757Wire Stories
Aerie Pharmaceuticals Announces Positive Phase 3 Topline Results for Netarsudil Ophthalmic Solution 0.02% Clinical Trial in Japan
Netarsudil Ophthalmic Solution 0.02% Once Daily Demonstrated Superiority to Ripasudil 0.4% Twice Daily DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical...
- 582News
Hong Kong Institute of Surveyors Building Surveyors Conference 2021
Navigating changes and challenges in surveying industry to enable sailing amidst the new normal HONG KONG SAR – Media OutReach – 12 October 2021...
- 636Wire Stories
China & International Automotive Infrared Night Vision System Markets Report 2021 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Automotive Infrared Night Vision System Research Report, 2021” report has been added to ResearchAndMarkets.com’s offering. This report combs through development...
